文献速递糖尿病垂体与肾上腺疾病

难以控制的2型糖尿病中皮质醇增多症的患病率

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2025-01-01

这项前瞻性观察研究对1057例HbA1c 7.5%-11.5%且使用≥2种降糖药的2型糖尿病患者行1 mg地塞米松抑制试验,皮质醇增多症患病率为23.8%(95% CI 21.3, 26.5),合并心脏病者达33.3%、使用≥3种降压药者达36.6%,34.7%的皮质醇增多症患者存在肾上腺影像学异常。

要点

  • 难以控制的2型糖尿病患者中皮质醇增多症患病率为23.8%(95% CI 21.3, 26.5)。
  • 合并心脏病者患病率33.3%,使用≥3种降压药者36.6%。
  • 皮质醇增多症患者中34.7%报告肾上腺影像学异常。

核心结论

  • 在尽管使用多种药物但控制不佳的2型糖尿病患者中,约四分之一存在皮质醇增多症,且其与高血糖相关。

研究设计与样本

  • 前瞻性观察研究,纳入HbA1c 7.5%-11.5%(58-102 mmol/mol)且使用两种及以上降糖药、伴或不伴微血管/大血管并发症或使用多种降压药的2型糖尿病患者,共1057例,采用1 mg地塞米松抑制试验筛查并排除导致假阳性的常见原因。

主要发现

  • 1057例参与者中252例地塞米松抑制试验后皮质醇未抑制,患病率23.8%(95% CI 21.3, 26.5)。
  • 合并心脏病者皮质醇增多症患病率为33.3%,使用三种及以上降压药者为36.6%。
  • 皮质醇增多症参与者中34.7%报告肾上腺影像学异常。
  • 使用钠-葡萄糖协同转运蛋白2抑制剂(比值比1.558)、最大剂量胰高血糖素样肽1受体激动剂(1.544)、替尔泊肽(1.981)、较高降压药数量(1.390)、较大年龄(1.316)、BMI<30 kg/m2(1.639)、非拉丁裔/西班牙裔(3.718)、使用贝特类(2.676)或镇痛药(1.457)与较高患病率相关(所有P<0.03)。

关键数值与推荐

  • 皮质醇增多症定义为地塞米松抑制试验后皮质醇>1.8 μg/dL(50 nmol/L)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control. RESEARCH DESIGN AND METHODS: Individuals with type 2 diabetes and HbA1c 7.5%-11.5% (58-102 mmol/mol) on two or more glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure-lowering medications were screened with a 1-mg dexamethasone suppression test. Common causes of false-positive DSTs were excluded. The primary end point was the prevalence of hypercortisolism, defined as post-DST cortisol >1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed with multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed. RESULTS: Post-DST cortisol was unsuppressed in 252 of 1,057 participants (prevalence 23.8%; 95% CI 21.3, 26.5). Hypercortisolism prevalence was 33.3% among participants with cardiac disorders and 36.6% among those taking three or more blood pressure-lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of sodium-glucose cotransporter 2 inhibitors (odds ratio 1.558), maximum-dose glucagon-like peptide 1 receptor agonists (1.544), tirzepatide (1.981), or a higher number of blood pressure-lowering medications (1.390); older age (1.316); BMI <30 kg/m2 (1.639); non-Latino/Hispanic ethnicity (3.718); and use of fibrates (2.676) or analgesics (1.457) were associated with higher prevalence (all P < 0.03). CONCLUSIONS: Hypercortisolism was associated with hyperglycemia in approximately one-quarter of individuals with inadequately controlled type 2 diabetes despite multiple medications.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Buse JB, Kahn SE, Aroda VR, et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care. 2025. PMID: 40249765. doi:10.2337/dc24-2841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。